Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-selection study of S-600918 in refractory chronic cough
2019-002283-27Phase 2Unknown
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in refractory chronic cough (RCC) and chronic idiopathic cough (CIC) comparing S-600918 dose arm(s) with Placebo (2 arms). Primary endpoint: Ratio of 24-hour cough frequency at Week 4 to baseline. Status: unknown.
02
Drugs
sivopixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on 2019-002283-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002283-27.